We read with interest the article by AZEVEDO et al. . The authors suggested that mycophenolate mofetil (MMF) may have a protective role against Pneumocystis pneumonia (PCP). Through a retrospective study, they noticed no PCP occurrence in a cohort of renal transplant recipients treated with MMF, despite the absence of trimethoprim-sulfamethoxazole (TMS) prophylaxis. We report herein a case of severe PCP which occurred in a renal transplant recipient after long-term MMF treatment and describe the genotyping of the fungus detected in this patient.
. In the three BAL specimens, a single and identical ITS 1 and 2 allele combination, B 1 a 4 , wild sequences of DHPS locus, and identical mtLSUrRNA sequences were observed. Thus, by using a multilocus genotyping at three independent loci, a single P. jirovecii genotype was identified, suggesting that the infection was clonal due to only one P. jirovecii strain.
In this study, we reported a case of severe PCP in a renal transplant recipient which occurred after long-term MMF treatment. It is noteworthy that the patient did not develop the infection until MMF treatment was interrupted, despite the absence of efficient PCP prophylaxis. PCP appears to be rare in patients with MMF treatment as revealed by HUSAIN & SINGH in a review article: in four controlled trials, none of a total 1068 renal transplant recipients who received MMF developed PCP 6 . These results suggest that the drug is active against P. jirovecii (human derived Pneumocystis) as it was established in rodent models for P. carinii (rat derived Pneumocystis) 12 . However, discontinuation of P. jirovecii prophylaxis for patients receiving MMF is not yet recommended.
We identified a single P. jirovecii genotype in three subsequent BALs performed during this PCP episode. The analysis of the DHPS locus was included in the multi-locus system we chose, since it has previously been suggested that P. jirovecii DHPS mutants have a significant impact on the outcome of PCP and patient mortality 3 . For our patient, it was improbable that death was related to such a correlation as no P. jirovecii DHPS mutant was detected. We identified a rare allele combination at the ITS locus. The allele combination B 1 a 4 [which corresponds to Jf as described by LEE et al. 8 (GenBank accession numbers, AF 013815 and AF 013826)] has only been reported in six instances, five concerning PCP cases among patients with HIV 1, 4, 5, 8 and one concerning a primary infection with P. jirovecii developed by infants 13 . A relationship between ITS allele combination and virulence has been suggested by MILLER & WAKEFIELD who identified the combination A 2 c 1 as a cause of severe pneumonia 10 . However, the ITS allele combination B 1 a 4 was not part of the panel investigated by MILLER et al. because of its rare occurrence.
In a previous study, by analyzing the ITS locus and sequencing a number of clones from three to five for each specimen, we observed a frequency of mixed infections up to 66% 11 , showing that P. jirovecii infection is not clonal in most cases. Conversely, in the present study we identified a single and identical ITS allele combination in one patient with PCP, despite examination of three BAL specimens retrieved over a 15 day period, and a high number of clones (a total of 18, data not shown). Furthermore, at each of the mtLSUrRNA and the DHPS loci, identical sequences were also detected. Our genotyping approach, which combined cloning and multi-locus sequence analysis performed on iterative BAL specimens within the same PCP episode reduced the risk of underlooking genotypes and enabled us to assess the presence of a single type in our patient.
However, we should consider the possibility that initially the infection may not have been clonal. The MMF target is the inositol monophosphate dehydrogenase (IMPDH) which appears to have different variants 17 that may conserve activity despite MMF treatment. Thus, the MMF treatment may have killed off susceptible strains leaving resistant strains that corresponded to the single genotype finally detected in our patient. In this case, the patient may have harbored the fungus, at least over a 6-month period after MMF treatment interruption and before developing the present PCP episode. This is consistent with previous studies which established that immunosuppressed patients can frequently be colonized by the fungus 11 . In fact, it cannot be ruled out that the P. jirovecii genotype corresponds to virulent organisms proliferating initially in a clonal context or secondarily after selection by MMF treatment. The severity of PCP in our patient may be partly related to his past history of long-term MMF treatment. The present case-report pleads in favor of P. jirovecii prophylaxis maintenance in transplant recipients even if the immunosuppressive therapy is based on MMF. 
